The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to […]
Journal of Commercial Biotechnology — January 2010 issue now available Read Post »
This is a guest post from Cliff Cramer, Director of the Healthcare and Pharmaceutical Management Program at Columbia Business School.
This is my initial response to the Kyoto Prize, which I was able to attend on a fellowship from Point
At a recent event on the comparative advantages of small molecule vs. biologic drugs, several themes emerged which led me
Is the practice of medicine impeding medical innovation? Read Post »
With the issue of data exclusivity for novel biologics re-emerging in the news, I’d like to present two arguments that
Biologic data exclusivity: The arguments for and against it Read Post »
I am honored to have been selected for the 2009 Kyoto Prize Journalism Fellowship, offered by Point Loma Nazarene University.
The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to
Journal of Commercial Biotechnology — October 2009 issue now available Read Post »
In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s
DCbiotech is a high-level networking group based in Washington DC. The objective is to bring together individuals working in, or
Introducing DCbiotech — High-level networking in the nation’s capital Read Post »
With two life science IPOs earlier this month, and seemingly fewer stories of biotechnology firm liquidations, it seems that the